ELVN

Enliven Therapeutics Inc

Oct 14 • 10:35AM ET

20.09

-0.59 -2.85 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ALNY IONS BMRN INCY NBIX PRTA EXEL ONC

| Held by: VTI IWM VXF IWO IBB SCHA VTWO XPH IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-2.00	Insider Own	29.31%	Shs Outstand	59.23M	Perf Week	-0.10%
Market Cap	1.19B	Forward P/E	-	EPS next Y	-2.21	Insider Trans	-1.21%	Shs Float	41.87M	Perf Month	8.59%
Enterprise Value	699.92M	PEG	-	EPS next Q	-0.43	Inst Own	76.06%	Short Float	13.61%	Perf Quarter	-6.38%
Income	-100.22M	P/S	-	EPS this Y	-2.00%	Inst Trans	20.06%	Short Ratio	12.12	Perf Half Y	16.87%
Sales	0.00M	P/B	2.44	EPS next Y	-14.64%	ROA	-24.12%	Short Interest	5.70M	Perf YTD	-10.71%
Book/sh	8.25	P/C	2.43	EPS next 5Y	-15.89%	ROE	-25.26%	52W High	30.03 -33.10%	Perf Year	-25.51%
Cash/sh	8.28	P/FCF	-	EPS past 3/5Y	43.93% 19.02%	ROIC	-20.52%	52W Low	13.30 51.05%	Perf 3Y	115.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.39% 5.78%	Perf 5Y	-76.60%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-3.53%	Oper. Margin	-	ATR (14)	1.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	32.58	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	50.31	Recom	1.10
Dividend Gr. 3/5Y	- -	Current Ratio	32.58	EPS Q/Q	-17.16%	SMA20	0.82%	Beta	0.78	Target Price	40.67
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	1.63%	Rel Volume	0.41	Prev Close	20.68
Employees	62	LT Debt/Eq	0.00	Earnings	Aug 13 AMC	SMA200	-0.74%	Avg Volume	470.34K	Price	20.09
IPO	Mar 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.72% -	Trades		Volume	40,643	Change	-2.85%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-16-25	Initiated	Goldman	Buy	$37
Dec-13-24	Initiated	BTIG Research	Buy	$42
Sep-09-24	Initiated	H.C. Wainwright	Buy	$37
Jun-11-24	Initiated	Robert W. Baird	Outperform	$32
Apr-09-24	Initiated	Mizuho	Buy	$34
Mar-29-23	Initiated	Jefferies	Buy	$27

Sep-12-25 09:55AM	Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know (Zacks)
Sep-09-25 12:00PM	Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-27-25 09:55AM	How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41% (Zacks)
Aug-25-25 06:20PM	Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting (PR Newswire)
Aug-13-25 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (PR Newswire) +5.80%
09:55AM	Loading…
Jul-18-25 09:55AM	Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect? (Zacks)
Jun-17-25 01:33PM	Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data (Insider Monkey) -5.59%
Jun-16-25 04:05PM	Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire) +5.39%
Jun-13-25 09:30AM	Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire) +11.44%
06:10AM	Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
06:02AM	Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress (PR Newswire)
May-22-25 04:05PM	Enliven Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-17-25 12:40PM	Enliven price target lowered to $27 from $36 at JonesResearch (TipRanks)
May-14-25 04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (PR Newswire) -10.41%
09:56AM	Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress (PR Newswire)
02:54PM	Loading…
Apr-22-25 02:54PM	Enliven Therapeutics: Awaiting Additional Trial Data (Seeking Alpha) +10.79%
Apr-02-25 04:03PM	Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting (PR Newswire) +5.19%
Mar-13-25 04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (PR Newswire)
Feb-25-25 04:05PM	Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (PR Newswire) -5.71%
Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
Nov-13-24 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire) -5.04%
Nov-07-24 04:05PM	Enliven Therapeutics to Present at the Jefferies London Healthcare Conference (PR Newswire)
Oct-18-24 04:38PM	Why this largely unknown company is one analyst's top biotech pick (Yahoo Finance Video)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +7.92%
Sep-30-24 04:52AM	Enliven Therapeutics ELVN-001 shows promise in Phase I CML trial (Clinical Trials Arena) +5.84%
Sep-28-24 09:35AM	Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Sep-26-24 08:50AM	Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going (Zacks)
Sep-18-24 04:05PM	Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML (GlobeNewswire) +6.02%
Sep-09-24 02:05PM	Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst (Benzinga) +7.28%
Sep-04-24 09:55AM	Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? (Zacks)
09:55AM	Loading…
Aug-16-24 09:55AM	Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet (Zacks)
Aug-13-24 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (GlobeNewswire)
May-29-24 04:05PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) -8.14% +5.67%
May-20-24 05:06PM	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing (MT Newswires)
May-14-24 10:54PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:01PM	Enliven Therapeutics Q1 Loss Narrows (MT Newswires)
04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (GlobeNewswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-11-24 03:44PM	Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program (Benzinga) +20.18%
07:55AM	Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Apr-09-24 04:05PM	Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 (GlobeNewswire) -5.58% +7.45%
Mar-23-24 01:51AM	Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares (GuruFocus.com)
Mar-19-24 08:30AM	Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates (GlobeNewswire) +38.77%
Mar-14-24 09:53PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.95%
04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-27-24 04:05PM	Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Jan-03-24 09:01AM	Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares (GuruFocus.com)
Nov-09-23 04:05PM	Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -7.97%
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace) +6.00%
Aug-10-23 04:05PM	Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-31-23 04:55PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.85%
May-11-23 04:05PM	Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)
Jan-01-01 12:00AM	Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data (Insider Monkey)

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Anish	CHIEF OPERATING OFFICER	Oct 07 '25	Sale	20.10	6,667	133,993	276,641	Oct 09 05:21 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 29 '25	Option Exercise	2.48	3,250	8,060	26,250	Oct 01 04:46 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 29 '25	Sale	20.40	3,250	66,291	23,000	Oct 01 04:46 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sep 26 '25	Sale	20.25	4,000	81,005	927,688	Sep 30 05:53 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 26 '25	Sale	20.06	3,700	74,228	915,392	Sep 30 05:51 PM
Hohl Benjamin	Officer	Sep 29 '25	Proposed Sale	20.01	4,500	90,045		Sep 29 05:19 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sep 23 '25	Sale	20.03	1,500	30,045	931,688	Sep 25 07:44 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 23 '25	Sale	20.03	2,800	56,084	919,092	Sep 25 07:42 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sep 19 '25	Sale	19.39	7,000	135,697	933,188	Sep 23 05:14 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 17 '25	Sale	19.09	5,000	95,473	922,892	Sep 19 07:12 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 19 '25	Sale	20.25	1,000	20,250	921,892	Sep 19 07:12 PM
Lyssikatos Joseph P	Officer	Sep 19 '25	Proposed Sale	19.93	12,500	249,125		Sep 19 05:32 PM
Kintz Samuel	Officer	Sep 17 '25	Proposed Sale	18.43	12,500	230,375		Sep 17 04:08 PM
Patel Anish	CHIEF OPERATING OFFICER	Sep 08 '25	Sale	20.24	6,667	134,957	283,308	Sep 10 08:12 PM
Patel Anish	Officer	Sep 08 '25	Proposed Sale	20.15	20,001	403,020		Sep 08 04:30 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 27 '25	Option Exercise	2.48	3,250	8,060	26,250	Aug 29 05:03 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 27 '25	Sale	20.63	3,250	67,039	23,000	Aug 29 05:03 PM
Hohl Benjamin	Officer	Aug 27 '25	Proposed Sale	20.32	5,250	106,680		Aug 27 04:44 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Aug 21 '25	Sale	20.01	7,500	150,099	940,188	Aug 21 06:46 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Aug 19 '25	Sale	19.62	5,000	98,118	947,688	Aug 21 06:46 PM
Kintz Samuel	PRESIDENT AND CEO	Aug 18 '25	Sale	20.02	10,393	208,106	929,999	Aug 20 04:36 PM
Kintz Samuel	PRESIDENT AND CEO	Aug 19 '25	Sale	20.00	590	11,800	929,409	Aug 20 04:36 PM
Lyssikatos Joseph P	Officer	Aug 19 '25	Proposed Sale	19.75	12,500	246,875		Aug 19 04:24 PM
Kintz Samuel	Officer	Aug 18 '25	Proposed Sale	20.22	12,500	252,750		Aug 18 04:21 PM
Patel Anish	CHIEF OPERATING OFFICER	Aug 07 '25	Sale	18.24	6,667	121,616	289,975	Aug 11 06:51 PM
Patel Anish	Officer	Aug 07 '25	Proposed Sale	18.84	6,667	125,606		Aug 07 04:19 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 28 '25	Option Exercise	2.48	3,250	8,060	26,250	Jul 30 05:57 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 28 '25	Sale	20.46	3,250	66,504	23,000	Jul 30 05:57 PM
Hohl Benjamin	Officer	Jul 28 '25	Proposed Sale	21.20	4,250	90,100		Jul 28 04:09 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jul 21 '25	Sale	22.29	12,500	278,646	952,688	Jul 23 06:52 PM
Kintz Samuel	PRESIDENT AND CEO	Jul 17 '25	Sale	22.52	12,500	281,518	940,392	Jul 21 07:21 PM
Lyssikatos Joseph P	Officer	Jul 21 '25	Proposed Sale	22.66	12,500	283,250		Jul 21 04:10 PM
Kintz Samuel	Officer	Jul 17 '25	Proposed Sale	21.46	12,500	268,250		Jul 17 04:13 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 10 '25	Option Exercise	2.48	1,000	2,480	24,000	Jul 14 05:07 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 10 '25	Sale	22.66	1,000	22,655	23,000	Jul 14 05:07 PM
Patel Anish	CHIEF OPERATING OFFICER	Jul 07 '25	Sale	19.79	6,667	131,951	296,642	Jul 09 07:29 PM
Patel Anish	Officer	Jul 07 '25	Proposed Sale	20.73	6,667	138,207		Jul 07 04:15 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 27 '25	Option Exercise	2.48	3,250	8,060	26,250	Jul 01 04:42 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 27 '25	Sale	20.91	3,250	67,956	23,000	Jul 01 04:42 PM
Hohl Benjamin	Officer	Jun 27 '25	Proposed Sale	21.52	4,250	91,460		Jun 27 04:01 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jun 20 '25	Sale	21.40	12,500	267,458	965,188	Jun 24 05:36 PM
Lyssikatos Joseph P	Officer	Jun 20 '25	Proposed Sale	21.57	12,500	269,625		Jun 20 04:02 PM
Kintz Samuel	PRESIDENT AND CEO	Jun 17 '25	Sale	22.18	12,500	277,292	952,892	Jun 18 06:22 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 13 '25	Option Exercise	2.48	3,000	7,440	26,000	Jun 17 04:24 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 13 '25	Sale	22.55	3,000	67,655	23,000	Jun 17 04:24 PM
Kintz Samuel	Officer	Jun 17 '25	Proposed Sale	23.09	12,500	288,625		Jun 17 04:15 PM
Hohl Benjamin	Officer	Jun 13 '25	Proposed Sale	19.99	3,000	59,980		Jun 13 04:08 PM
Patel Anish	CHIEF OPERATING OFFICER	Jun 09 '25	Sale	20.34	6,667	135,574	303,309	Jun 11 06:25 PM
Patel Anish	Officer	Jun 09 '25	Proposed Sale	20.74	6,667	138,274		Jun 09 04:21 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jun 03 '25	Sale	20.03	7,500	150,220	977,688	Jun 05 04:55 PM
Kintz Samuel	PRESIDENT AND CEO	Jun 03 '25	Sale	20.05	7,500	150,352	965,392	Jun 05 04:53 PM
Kintz Samuel	Officer	Jun 03 '25	Proposed Sale	19.14	7,500	143,550		Jun 03 05:34 PM
Lyssikatos Joseph P	Officer	Jun 03 '25	Proposed Sale	19.14	7,500	143,550		Jun 03 05:14 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	May 27 '25	Option Exercise	2.48	3,250	8,060	26,250	May 29 05:38 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	May 27 '25	Sale	16.18	3,250	52,593	23,000	May 29 05:38 PM
Hohl Benjamin	Officer	May 27 '25	Proposed Sale	16.40	3,250	53,300		May 27 04:03 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 19 '25	Sale	16.31	5,000	81,534	985,188	May 21 06:31 PM
Kintz Samuel	PRESIDENT AND CEO	May 19 '25	Sale	16.49	5,000	82,453	972,892	May 21 06:29 PM
Kintz Samuel	Officer	May 19 '25	Proposed Sale	16.86	5,000	84,300		May 19 04:22 PM
Lyssikatos Joseph P	Officer	May 19 '25	Proposed Sale	16.86	5,000	84,300		May 19 04:21 PM
Patel Anish	CHIEF OPERATING OFFICER	May 07 '25	Sale	18.39	6,667	122,579	309,976	May 09 06:48 PM
Patel Anish	Officer	May 07 '25	Proposed Sale	19.69	6,667	131,273		May 07 04:11 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 01 '25	Sale	20.07	5,030	100,966	992,658	May 05 06:43 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 02 '25	Sale	20.01	2,470	49,424	990,188	May 05 06:43 PM
Kintz Samuel	PRESIDENT AND CEO	May 01 '25	Sale	20.08	5,330	107,007	980,062	May 05 06:42 PM
Kintz Samuel	PRESIDENT AND CEO	May 02 '25	Sale	20.00	2,170	43,409	977,892	May 05 06:42 PM
Lyssikatos Joseph P	Officer	May 01 '25	Proposed Sale	18.94	7,500	142,050		May 01 04:03 PM
Kintz Samuel	Officer	May 01 '25	Proposed Sale	18.94	7,500	142,050		May 01 04:02 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 28 '25	Option Exercise	2.48	3,250	8,060	26,250	Apr 30 06:59 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 28 '25	Sale	18.69	3,250	60,738	23,000	Apr 30 06:59 PM
Hohl Benjamin	Officer	Apr 28 '25	Proposed Sale	18.21	3,250	59,182		Apr 28 04:19 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 21 '25	Sale	16.07	5,000	80,366	997,688	Apr 23 05:09 PM
Kintz Samuel	PRESIDENT AND CEO	Apr 17 '25	Sale	16.42	5,000	82,096	985,392	Apr 21 05:55 PM
Lyssikatos Joseph P	Officer	Apr 21 '25	Proposed Sale	16.53	5,000	82,650		Apr 21 04:28 PM
Kintz Samuel	Officer	Apr 17 '25	Proposed Sale	16.07	5,000	80,350		Apr 17 04:19 PM
Patel Anish	Member of immediate family of	Apr 14 '25	Proposed Sale	16.51	2,010	33,185		Apr 14 04:54 PM
Patel Anish	Member of immediate family of	Apr 14 '25	Proposed Sale	16.51	2,010	33,185		Apr 14 04:48 PM
Patel Anish	CHIEF OPERATING OFFICER	Apr 07 '25	Sale	18.04	6,667	120,269	316,643	Apr 09 04:25 PM
Patel Anish	Officer	Apr 07 '25	Proposed Sale	18.69	6,667	124,606		Apr 07 04:09 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 27 '25	Option Exercise	2.48	3,250	8,060	26,250	Mar 31 07:37 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 27 '25	Sale	21.33	3,250	69,321	23,000	Mar 31 07:37 PM
Hohl Benjamin	Officer	Mar 27 '25	Proposed Sale	20.58	4,250	87,465		Mar 27 04:01 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 24 '25	Option Exercise	2.48	1,000	2,480	24,000	Mar 26 07:37 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 24 '25	Sale	22.50	1,000	22,504	23,000	Mar 26 07:37 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Mar 19 '25	Sale	20.61	12,500	257,575	1,002,688	Mar 21 05:49 PM
Kintz Samuel	PRESIDENT AND CEO	Mar 17 '25	Sale	20.83	12,500	260,320	990,392	Mar 19 05:42 PM
Lyssikatos Joseph P	Officer	Mar 19 '25	Proposed Sale	20.28	12,500	253,500		Mar 19 04:18 PM
Kintz Samuel	Member of immediate family of	Mar 18 '25	Proposed Sale	21.04	21,531	453,012		Mar 18 04:14 PM
Kintz Samuel	Member of immediate family of	Mar 18 '25	Proposed Sale	21.04	21,531	453,012		Mar 18 04:06 PM
Kintz Samuel	Officer	Mar 17 '25	Proposed Sale	20.74	12,500	259,250		Mar 17 04:14 PM
Patel Anish	Member of immediate family of	Mar 17 '25	Proposed Sale	20.74	2,500	51,850		Mar 17 04:08 PM
Patel Anish	Member of immediate family of	Mar 17 '25	Proposed Sale	20.74	2,500	51,850		Mar 17 04:04 PM
Patel Anish	CHIEF OPERATING OFFICER	Mar 07 '25	Sale	21.44	6,667	142,936	323,310	Mar 11 05:18 PM
Patel Anish	Officer	Mar 07 '25	Proposed Sale	21.46	6,667	143,074		Mar 07 04:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 04 '25	Option Exercise	2.48	10,000	24,800	23,000	Mar 06 06:02 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 27 '25	Option Exercise	2.48	3,250	8,060	16,250	Mar 03 08:07 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 27 '25	Sale	20.41	3,250	66,327	13,000	Mar 03 08:07 PM
Hohl Benjamin	Officer	Feb 27 '25	Proposed Sale	20.28	4,250	86,190		Feb 27 04:10 PM
Patel Anish	Member of immediate family of	Feb 14 '25	Proposed Sale	21.50	2,500	53,750		Feb 14 05:02 PM
Patel Anish	Member of immediate family of	Feb 14 '25	Proposed Sale	21.50	2,500	53,750		Feb 14 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELVN

Enliven Therapeutics Inc

Upgrade your FINVIZ experience